Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10039374 | 0.79 | KMT2A (0.60) | KMT2AMEN1KDM4EGAAMAPT | |
| SCHEMBL17286932 | 0.75 | KMT2A (0.60) | KMT2AMEN1KDM4EGAAMAPT | |
| SCHEMBL16353106 | 0.75 | KMT2A (0.60) | KMT2AMEN1KDM4EGAAMAPT | |
| SCHEMBL8265150 | 0.74 | ADORA2A (0.66) | KMT2AMEN1KDM4EMAPTTP53 | |
| SCHEMBL13561140 | 0.74 | MEN1 (1.00) | KMT2AMEN1KDM4EGAAMAPT | |
| SCHEMBL14970094 | 0.74 | TSHR (0.56) | KMT2AMEN1KDM4EGAAMAPT | |
| SCHEMBL13611581 | 0.73 | KDR (0.53) | KMT2AMEN1KDM4EMAPTTP53 | |
| SCHEMBL18900464 | 0.72 | KMT2A (0.72) | KMT2AMEN1KDM4EGAAMAPT | |
| SCHEMBL21031204 | 0.72 | KMT2A (0.53) | KMT2AMEN1KDM4EMAPTTP53 | |
| SCHEMBL18562524 | 0.71 | KMT2A (0.55) | KMT2AMEN1KDM4EMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288398-B2 | Antiproliferative pyrimidyl, fused pyrimidyl and pyrimidyl hydrazones | MERCK SERONO SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20120238575-A1 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20080287474-A1 | Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones | LABORATOIRES SERONO SA (CH) | 2008-11-20 | — | — | US | disclosed |
| EP-1957469-A1 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES | Laboratoires Serono SA (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007065940-A1 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES | LABORATOIRES SERONO S.A. (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287474-A1 | Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones | TYMP, DHFR, DPYD | KMT2A 2069/4885MEN1 1194/4885KDM4E 3687/4885 |
| US-20120238575-A1 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES | TYMP, DHFR, DPYD | KMT2A 2069/4885MEN1 1194/4885KDM4E 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.